B. Berns

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

J. Larkin, L. Pickering, M. Gore, 2010, British Journal of Cancer.

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

A. Tolcher, K. Papadopoulos, A. Patnaik, 2013, Cancer Chemotherapy and Pharmacology.

Moving clinical drug development to early-stage disease

B. Berns, 2007 .

How can biomarkers become surrogate endpoints

M. Scheulen, P. Démolis, B. Berns, 2007 .

Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

Hugh M. Davis, U. Prabhakar, Q. Jiao, 2010, Clinical Cancer Research.

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

J. Rossi, N. James, U. Prabhakar, 2010, British Journal of Cancer.

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

A. Dalgleish, H. Zwierzina, J. Smyth, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

J. Rossi, U. Prabhakar, S. Négrier, 2010, British Journal of Cancer.